Ftse Mib
33.863,60
0,38%
DAX
17.988,57
0,46%
S&P 500
5.064,20
0,91%
NASDAQ
15.840,96
1,51%
Bitcoin
58.895,24
-0,38%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Lipella Pharmaceuticals Inc (LIPO) Lipella Pharmaceuticals Inc (LIPO) Notizie

Lipella Pharmaceuticals Inc

LIPO
0,75
0,00 (0,00%)
Pre Mercato
Ultimo aggiornamento: 10:00:00
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
17/4/202414:00GLOBELipella Pharmaceuticals Expands its Advisory Board to..
05/4/202414:00GLOBELipella Pharmaceuticals to Publish Abstract Detailing..
03/4/202414:00GLOBELipella Pharmaceuticals Announces FDA Type C Meeting for..
07/3/202421:23GLOBEPRISM MarketView Spotlights Lipella Pharmaceuticals as it..
06/3/202423:05EDGAR2Form SC 13D/A - General statement of acquisition of..
06/3/202423:03EDGAR2Form SC 13D/A - General statement of acquisition of..
05/3/202414:00GLOBELipella Pharmaceuticals Announces FDA Clearance of IND for..
27/2/202423:04EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
27/2/202422:51EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
20/2/202414:00GLOBELipella Pharmaceuticals to Present at PropThink Digital..
09/2/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
07/2/202423:29EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
01/2/202422:09EDGAR2Form S-3 - Registration statement under Securities Act of..
25/1/202422:06EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
03/1/202422:59EDGAR2Form SC 13G - Statement of acquisition of beneficial..
20/12/202314:00GLOBELipella Pharmaceuticals Marks Successful First Year with..
28/11/202323:28EDGAR2Form 8-K - Current report
22/11/202322:05EDGAR2Form 8-K - Current report
14/11/202312:22EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
14/11/202312:14EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/11/202314:00PRNUSFDA Grants Orphan Designation for Lipella's LP-310 Drug..
09/11/202322:07EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
01/11/202321:06EDGAR2Form S-1 - General form for registration of securities under..
25/10/202322:05PRNUSLipella Pharmaceuticals Announces Closing of $2 Million..
24/10/202314:00PRNUSLipella Pharmaceuticals Announces $2 Million Private..
20/10/202314:00PRNUSLipella Pharmaceuticals Announces FDA Clearance of IND for..
10/10/202322:05EDGAR2Form DEF 14A - Other definitive proxy statements
21/9/202314:30PRNUSLipella Pharmaceuticals' Phase 2a Clinical Study Results..
11/9/202313:38EDGAR2Form 8-K - Current report
14/8/202322:16EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
14/8/202322:04EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202322:30EDGAR2Form 8-K - Current report
02/8/202322:05EDGAR2Form 8-K - Current report
15/5/202315:17PRNUSLipella Pharmaceuticals Reports First Quarter 2023 Financial..
Apertura: Min: Max:
Chiusura: 0,75

La tua Cronologia

NASDAQ
LIPO
Lipella Pharmaceuticals
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network